WO2008071058A1 - Dérivé macromoléculaire modifié par un groupe mercapto et matériau réticulé - Google Patents
Dérivé macromoléculaire modifié par un groupe mercapto et matériau réticulé Download PDFInfo
- Publication number
- WO2008071058A1 WO2008071058A1 PCT/CN2007/002864 CN2007002864W WO2008071058A1 WO 2008071058 A1 WO2008071058 A1 WO 2008071058A1 CN 2007002864 W CN2007002864 W CN 2007002864W WO 2008071058 A1 WO2008071058 A1 WO 2008071058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- solution
- derivative
- group
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/02—Alkyl or cycloalkyl ethers
- C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
- C08B11/14—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with nitrogen-containing groups
- C08B11/15—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with nitrogen-containing groups with carbamoyl groups, i.e. -CO-NH2
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
Definitions
- the present invention relates to a compound, in particular to a polymer thiolated modified derivative; in addition, the present invention also relates to a corresponding disulfide crosslinked material and a sulfhydryl reactive crosslinker crosslinked material of the polymer thiolated modified derivative. .
- Polymer thiolated modified derivatives have many important biomedical uses, such as chemically active modification of various small molecule drugs and polypeptide protein drugs, preparation of various crosslinked polymer materials, and the like. These novel materials can be used as a cell growth substrate, a wound repair regeneration matrix, a drug sustained release carrier, a wound dressing, an in situ embedded cell matrix, and the like, and have important applications in the biomedical field.
- thiolated modified macromolecular derivatives there are few kinds of such thiolated modified macromolecular derivatives, and only the polymer thiolated modified derivatives disclosed by Shu et al. in Biomacromolecules, 3, 1304, 2002 have a good application prospect.
- Such polymeric thiolated modified derivatives have the following structure:
- P is a polymer compound residue.
- the structure and properties of the polymer thiolated modified derivatives of these two structures are single and cannot effectively satisfy various biomedical applications.
- the high molecular thiolated modified derivatives of these two structures have short side chains, which restrict the collision probability of the sulfhydryl groups with other chemical functional groups during further chemical modification and crosslinking, and the chemical reaction performance is not good. Therefore, it has important significance to prepare a polymer thiolated derivative having an adjustable side chain molecular structure and chemical properties.
- One of the technical problems to be solved by the present invention is to provide a new class of polymer thiolated modified derivatives having important biomedical uses, which have adjustable molecular structure and chemical properties of side chains.
- the second technical problem to be solved by the present invention is to provide a cross-linking material of a polymer thiolated modified derivative which is cross-linked by disulfide bonds.
- the third technical problem to be solved by the present invention is to provide a high molecular thiolated modified derivative crosslinked material which is crosslinked by a sulfhydryl reactive crosslinking agent.
- the invention adopts a polymer compound with a carboxyl group in a side chain as a raw material, and synthesizes a novel method by a chemical preparation method.
- a thiolated modified macromolecular derivative are adjustable side chain molecular structure and chemical properties and have important applications in the field of biomedicine.
- the polymer thiolated modified derivative of the present invention is represented by the following formula (I) or ( ⁇ ):
- ⁇ And! ⁇ may have the same or different chemical structures, and the polymer thiolated modified derivative has a molecular weight of 1,000 to 5,000,000.
- the above P refers to a polymer compound residue having a carboxyl group in a side chain, and at least one of the polymer compound side chain carboxyl groups is modified to a mercapto group.
- the polymer compound having a carboxyl group in the side chain includes a polysaccharide, a protein, a synthetic polymer and the like.
- the polysaccharide includes chondroitin sulfate, dermatan, heparin, heparin, alginic acid, hyaluronic acid, dermatan sulfate, pectin, carboxymethylcellulose, carboxymethyl chitosan, etc.
- Molecules include polyacrylic acid, polyaspartic acid, polytartaric acid, polyglutamic acid, polyfumaric acid, etc. and their salt forms; proteins include collagen, alkaline gelatin, acid gelatin, basic gene recombinant gelatin Acidic recombinant gelatin protein, elastin, core proteoglycan laminin fiber binding protein, and the like.
- the polymer compound having a carboxyl group in the side chain is preferably chondroitin sulfate, heparin, heparinoid, alginic acid, hyaluronic acid, polyaspartic acid, polyglutamic acid, and a salt thereof (such as a sodium salt, a potassium salt, etc.).
- Particularly preferred are chondroitin sulfate, heparin, hyaluronic acid, and their salt forms (e.g., sodium salts, potassium salts, etc.), and basic gelatin proteins, acidic gelatin proteins.
- the above-mentioned anthracene group means -(CH 2 )-- ( ⁇ is an integer of 1 to 15).
- ⁇ is an integer of 1-8.
- the above substituted alkylene group means an alkylene group in which at least one hydrogen atom is substituted with a group such as a lower sulfhydryl group, a hydroxyl group, an amino group, a decyloxy group, a phenyl group or an ester group.
- aromatic group means an aromatic phenyl group, a naphthyl group or the like. Phenyl is preferred.
- the above polyether group means -[(CHR)tician0] n -, wherein R is a lower fluorenyl group, n is an integer of 1 to 10, and m is an integer of 1 to 500.
- R is a hydrogen atom, and n is equal to 2, respectively. , 3 and 4.
- the above lower sulfhydryl group means a linear or branched fluorenyl group having 1 to 8 carbon atoms.
- a linear or branched fluorenyl group having 1 to 8 carbon atoms For example: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, pentyl, neopentyl, hexyl, heptyl, octyl and the like.
- a linear or branched fluorenyl group having 1 to 4 carbon atoms is preferred, and a methyl group or an ethyl group is particularly preferred.
- propyl is preferred.
- the above decyloxy group means a linear or branched alkoxy group having 1 to 6 carbon atoms.
- a branched or linear alkoxy group having 1 to 4 carbon atoms is preferred, and a methoxy group and an ethoxy group are particularly preferred.
- the above ester group means -C(0) 0R, wherein R is the above lower fluorenyl group.
- R is the above lower fluorenyl group.
- Preferred are a methyl ester group, an ethyl ester group, a propyl ester group and a butyl ester group.
- a preferred compound of the invention is a neutralized R 2 representing an anthranylene group. Most preferred is! ⁇ and R 2 are an anthracene group having 1 to 8 carbon atoms.
- the polymer thiolated modified derivative of the present invention has the following chemical structure characteristics -
- the preparation of the polymer thiolated modified derivative of the formula (I) or (II) of the present invention generally employs a hydrazide/carbodiimide coupling chemistry.
- the basic principle is that the side chain carboxyl group of the polymer compound forms an active intermediate under the activation of the carbodiimide, and then the amino nucleophilic attacking active intermediate of the dithiodihydrazide forms an adduct, and finally the adduct of the second The sulfur bond is reduced to a free sulfhydryl group and purified to give the product.
- DGDTPDH dithiodipropionate diacyl glycine dihydrazide
- DADTPDH dithiodipropionate bisylalanine dihydrazide
- DHADTPDH Dithiodipropionate bis(hydroxy)aminoacetic acid dihydrazide
- DPDTPDH dithiodipropionate bisamidopropionic acid dihydrazide
- DBDTPDH disulfide Didipropionate diamidobutanoic acid dihydrazide
- DBDTPDH dithiodibutyric acid diacyl glycine dihydrazide
- DPDTBDH dithiodibutyric acid diacyl Aminopropionate dihydrazide
- DPDTBDH dithiodibutyric acid diacyl Aminopropionate dihydrazide
- a preparation method of the generalized thiolated modified derivative of the formula (I) and ( ⁇ ) of the present invention is as follows:
- the side chain carboxyl group of the polymer compound is in 1-ethyl-3-(3-dimethylaminopropyl)
- the disulfide bond of the final adduct is hydrogenated with a hydroxy thiol, dithiothreitol or borohydride
- the reducing agent such as sodium is reduced to a free sulfhydryl group, and the thiolated modified derivative of the formula (I) or (II) of the present invention can be obtained by dialysis purification to remove impurities.
- the following are chemical synthesis routes and chemical structural formulas in which R, and R 2 are an anthracene group, a substituted anthracen
- the macromolecular thiolated modified derivative of the formula ⁇ ) or ( ⁇ ) of the present invention when both 1 and 2 are an anthracene group, is a preferred compound of the present invention, and its chemical structure is as follows:
- (1) represents a structural formula of the polymer thiolated derivative of the formula (I) in which both 1 and 1 are 2 alkylene groups; (2) represents an alkylene group of both 1 and 1 and 2;
- the general formula (II) of the polymer thiolated derivative of the present invention has a structural formula (i, j, m, n are all integers greater than 1).
- R 2 is a fluorenylene group having 2 and 3 carbon atoms
- R is a carbon number of 1 to 5, respectively.
- the sulfhydryl group, P is a residue of chondroitin sulfate, heparin, hyaluronic acid and their salt forms (such as sodium salt, potassium salt, etc.), alkaline gelatin protein, acid gelatin protein, etc., and its chemical structural formula is as follows :
- (1) is a dithiodipropionate diacyl glycine dihydrazide modified polymer thiolated derivative (P-DGDTPDH); (2) is dithiodipropionate bisylalanine dihydrazide Modified polymer thiolated derivative (P-DADTPDH); (3) is dithiodibutyric acid diacyl glycine dihydrazide modified macromolecular derivative (P-DGDTBDH); (4) is disulfide Di-n-butyric acid bis-alanine dihydrazide-modified polymer thiolated derivative (P-DADTBDH); (5) is bis-succinic acid bisacyl cystamine dihydrazide modified polymer thiolated derivative (P -DSCDH); (6) is a bis-glutaric acid bisacylamine dihydrazide-modified polymer thiolated derivative (P-DGCDH); (7) is adipic acid acyl cystamine dihydrazide modification
- the thiolation modification preparation process does not significantly change the molecular weight and its distribution, and generally the molecular weight and distribution of the general formula (I) or ( ⁇ ) polymer thiolated modified derivative of the present invention and the starting material (the carboxyl group in the side chain is high)
- the molecular weight of the molecular compound and its distribution are substantially the same.
- the molecular weights of different starting materials vary widely, usually between 1,000 and 5 million; their molecular weight distributions also vary widely, such as the broad molecular weight distribution of gelatin.
- the molecular weight and distribution of the starting material do not affect the thiolation modification process, and do not affect the polymer thiolated modified derivative of the formula (I) or (II) of the present invention. Preparation.
- the general formula (I) or ( ⁇ ) polymer thiolated modified derivative of the present invention has many beneficial effects.
- the invention adopts the chemical bonding mode of the hydrazide bond to carry out the thiolation modification, and has many remarkable advantages such as mild preparation conditions, high yield, high degree of modification and controllability.
- the invention of the general formula (I) or ( ⁇ ) polymer thiolated modified derivative innovatively introduces an amide bond, the chemical structure of the side chain is flexible and the performance is adjustable. Studies have shown that the general formula (I) or ( ⁇ ) polymer thiolated modified derivatives of the present invention have the following two beneficial effects:
- the length and structure of the side chain can be flexibly adjusted by introducing an amide bond.
- the length of the side chains will greatly affect the reactivity of the sulfhydryl groups (Shu et al, Biomaterials 24, 3825, 2003).
- the amide bond is a strong electron withdrawing group, and the introduction of the side chain amide bond of the compound of the present invention is in a large range
- the degree of ionization constant (pK a ) of the terminal sulfhydryl group is affected, however this is related to the way the amide bond is connected.
- the carbonyl group in the side chain amide bond of the macromolecular amide bond of the general formula (I) of the present invention is similar to the terminal sulfhydryl group, and the ionization of the terminal sulfhydryl group is enhanced.
- the formula (II) of the present invention The nitrogen atom of the side chain amide bond of the polymer thiolated modified derivative is similar to the terminal sulfhydryl group, which weakens the ionization of the terminal thiol group! ⁇ Raised).
- the side chain linking fragments disclosed by Shu et al. in Biomacromolecules, 3, 1304, 2002 and WO 2004/03716 are polymerized thiolated modified derivatives of the fluorenylene group (carbon number 2 and 3).
- the thiol radicalization constant of the polymer thiolated modified derivative of the formula (I) of the present invention (pKJ is reduced by about 0.1 to 0.4), and the polymer thiolated modified derivative of the formula (II) of the present invention
- the thiol ionization constant (pKJ is increased by about 0.2 to 0.7). Therefore, the terminal fluorenyl group of the polymer thiolated modified derivative of the formula (I) of the present invention is more active, and the polymer thiol group of the formula ( ⁇ ) of the invention is more active.
- the terminal thiol group of the modified derivative is more stable.
- the macromolecular thiolated modified derivative of the formula (I) or (II) of the present invention has many unique properties compared with the disclosed macromolecular thiolated modified derivative, and can be selected according to the needs of practical applications.
- the following specific polymer thiolated derivatives of hyaluronic acid (HA) are further exemplified to further illustrate the beneficial effects of the general formula (I) or (II) polymer thiolated modified derivatives of the present invention:
- the above compounds have the same structure on the terminal oxime side, wherein (a) is a polymer thiolated modified derivative disclosed by Shu et al. in Biomacromolecules, 3, 1304, 2002 and WO 2004/03716; (b) is the present invention
- the polymer thiolated modified derivative of the formula (I); (c) is a polymer thiolated modified derivative of the formula (II) of the invention.
- the thiol-reactive activity of the polymer thiolated modified derivative (b) is much higher than that of (a), and its ability to form a disulfide-crosslinked gel is improved by about 50%; and the polymer thiolated modified derivative (c)
- the sulfhydryl reactivity is much lower than (a), and its sulfhydryl stability can be more than doubled.
- the polymer thiolated modified derivative of the formula (I) or (II) of the present invention has at least one side chain free sulfhydryl group which can be reoxidized under suitable conditions to form a disulfide bond.
- Medium-strength oxidants such as oxygen, low-concentration hydrogen peroxide, iodine, and iron trivalent ions can form a disulfide bond by free sulfhydryl groups, thereby preparing a polymer.
- Cross-linking materials are examples of cross-linking materials.
- disulfide bonds are usually affected by the pH of the solution: Under alkaline conditions, the sulfhydryl groups are ionized into sulfur anions, reflecting high activity, even if oxygen in the air can rapidly promote the formation of disulfide bonds; The ionization of the sulfhydryl group is inhibited, the reactivity is lowered, and the sulfhydryl group is relatively stable.
- the thiol group of the polymer thiolated modified derivative of the formula (I) of the present invention can produce a disulfide-bonded cross-linking material even under neutral conditions and weak oxidizing agents; and the formula (II) of the present invention
- the thiol group of the polymer thiolated modified derivative is relatively stable, and it is required to rapidly form a disulfide crosslinked material under the action of weakly basic or strong oxidizing agent.
- the preparation method of the disulfide-bonded polymer thiolated modified derivative crosslinked material of the invention is simple and reliable, and the product is flexible and variable.
- a commonly used preparation method is to prepare one or more polymer thiolated modified derivatives of the general formula (I) or ( ⁇ ) into an aqueous solution or a mixed aqueous solution, and use room temperature air under neutral or weakly alkaline conditions. Oxidation to prepare a disulfide-bonded cross-linking material; or under weakly acidic or acidic conditions, a disulfide-bonded cross-linking material is prepared by oxidation with a stronger oxidizing agent such as low-concentration hydrogen peroxide or iron trivalent ions.
- the one-component and two-component disulfide-crosslinked polymer thiolated modified derivative crosslinked materials of the present invention are represented by the following general formula (III), (IV) or (V):
- P 2 is a residue of a polymer compound having a carboxyl group in a side chain, and the definition thereof is the same as defined above.
- ⁇ and R 2 are as defined above;
- R 3 and R 4 are the same as ⁇ and R 2 ; and
- R 2 , R 3 may have the same or different chemical structures.
- 1 ⁇ and the same it is a one-component cross-linking material, when and! ⁇
- it is a two-component cross-linked material.
- the three-component or three-component disulfide-crosslinked polymer thiolated modified derivative cross-linking material of the present invention may be modified by three or more kinds of polymer thiolation of the general formula (I) or (II).
- the preparation of a derivative is characterized in that three or more polymer compounds are contained by a disulfide bond to form a crosslinked material.
- the thiol-reactive cross-linking agent cross-linked polymer thiolated modified derivative cross-linking material of the present invention comprises one or more novel polymer thiolated modified derivatives of the formula (I) or (II) and a mercapto group. Reactive activity Preparation of crosslinkers.
- the thiol-reactive functional groups used in the present invention include maleimide, vinyl sulfone, ⁇ , ⁇ unsaturated acrylate, ⁇ , ⁇ unsaturated methacrylate, halo propionate, halopropionamide, dithio Pyridine, hydrazine-hydroxysuccinimide activated ester, and the like.
- the thiol-reactive cross-linking agent used in the present invention contains at least two reactive functional groups of polyethylene glycol (referred to as PEG) derivatives, such as two-arm, three-arm, four-arm, eight-arm or more arms.
- PEG polyethylene glycol
- Alcohol derivatives which have the following typical chemical structure:
- Double-arm polyethylene glycol crosslinker Double-arm polyethylene glycol crosslinker
- G, G 2 , G 3 , G 4 , G 5 , G 6 , G 7 and G 8 are the above-mentioned thiol-reactive functional groups such as maleimide, vinylsulfone, ⁇ , ⁇ -unsaturated acrylate, ⁇ , ⁇ unsaturated methacrylate, halopropionate, halopropionamide, dithiopyridine or hydrazine-hydroxysuccinimide, etc., which may have all the same, partially identical or all different chemical structures ;
- PEG means a segment having a CH 2 CH 2 0 repeating unit having a molecular weight of 100 to 1,000,000.
- the general preparation method of the cross-linked polymer thiolated modified derivative cross-linking material of the sulfhydryl reactive cross-linking agent of the present invention comprises the modification of one or more novel polymer thiol groups of the formula (I) or ( ⁇ )
- the derivative is made into an aqueous solution or a mixed aqueous solution, and the pH of the solution is adjusted to be neutral.
- the aqueous solution of the above-mentioned thiol-reactive cross-linking agent is added, and after uniformly mixing, it is allowed to stand at room temperature for a while to form a gel, thereby obtaining a cross-linked material.
- the thiol group of the polymer thiolated modified derivative of the formula (I) of the invention is more active and reacts faster with the crosslinking agent; and the thiol group of the polymer thiolated modified derivative of the formula (II) of the invention is more Stable, the reaction with the crosslinker is relatively slow.
- the polymer thiolated modified derivative of the formula (I) and the above-mentioned double-armed polyethylene glycol sulfhydryl reactive crosslinking agent as an example, the one-component and two-component sulfhydryl reactive crosslinking agent of the present invention is crosslinked.
- the polymer thiolated modified derivative crosslinked material has the structure shown below:
- ⁇ ⁇ 2 is a residue of a polymer compound having a carboxyl group in a side chain, and its definition is the same as defined above; R, R 2 , R 3 and R 4 are as defined above; and R 2 , R 3 , R 4 may be Have the same or different chemical structures.
- P, and P 2 are the same, it is a one-component cross-linking material, when! ⁇ And! ⁇
- the polymer thiolated modified derivative crosslinked material may also be prepared by co-crosslinking two or more kinds of the above-mentioned two-arm polyethylene glycol sulfhydryl reactive cross-linking agent.
- one or more multi-arm polyethylene glycol derivative crosslinkers (such as a three-arm polyethylene glycol derivative crosslinker, a four-arm polyethylene glycol derivative crosslinker, an eight-arm polyether)
- a diol derivative crosslinking agent or the like is used to prepare a polymer thiolated modified derivative crosslinked material.
- the cross-linking material of the general formula ( ⁇ ) polymer thiolated modified derivative crosslinked with the thiol reactive crosslinking agent and the crosslinked material of the generalized thiolated modified derivative of the general formula (I) have a similar structure.
- the cross-linking material of the polymer thiolated modified derivative crosslinked by the three-component or three-component sulfhydryl reactive cross-linking agent of the present invention may be three or more kinds of the general formula (I) or ( ⁇ ) polymer.
- Preparation of thiolated modified derivatives The usual preparation route is to first prepare a mixed solution of three or more kinds of polymer thiolated modified derivatives of the formula (I) or ( ⁇ ), and then adjust the pH of the solution to be neutral, adding one or more
- the above polyethylene glycol sulfhydryl reactive derivative crosslinker is prepared to prepare a multicomponent crosslinked material.
- Figure 1 is a hydrogen atom nuclear magnetic resonance spectrum and an important chemical shift peak of a low-substituted derivative in Example 4 of the present invention (D 2 0 is a solvent);
- Example 2 is a hydrogen atom nuclear magnetic resonance spectrum and an important chemical shift peak of a highly substituted derivative in Example 4 of the present invention (D 2 0 is a solvent);
- FIG. 3 is a schematic view showing the morphology of cells on the surface of a blank cell culture plate in Example 20 of the present invention
- FIG. 4 is a cross-linked hyaluronic acid-gelatin two-component water of cells in polyethylene glycol diacrylate in Example 20 of the present invention. Schematic diagram of the surface of the gel.
- Example 1 Synthesis of dithiodipropionate diacyl glycine dihydrazide (DGDTPDH) 10 g of dithiodipropionic acid (Aldrich, USA) and 50 ml of anhydrous dimethylformamide were added to a 1000 ml beaker. After stirring at room temperature, 17.0 g of carbonyldiimidazole (Aldrich, USA) was added. At this point the solution produced a large amount of carbon dioxide bubbles and a white precipitate. The reaction was carried out under reduced pressure at room temperature for 3 hours Then, 14.7 g of glycine ethyl ester hydrochloride (Aldrich, USA) was added, and the reaction was stirred for 1 hour.
- DTDTPDH dithiodipropionate diacyl glycine dihydrazide
- Sodium hyaluronate (molecular weight 62 to 1.15 million, NovaMatrix FMC BI0P0LYMER, USA) 1 g Dissolved in 200 ml of distilled water to obtain a clear transparent solution.
- 1.32 g of DGDTPDH prepared in Example 1 was added and dissolved by stirring.
- the pH of the solution was adjusted to 4.75 with 0.1 mol/L hydrochloric acid, and 0.36 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Aldrich, United States), electromagnetic stirring.
- Sodium hyaluronate (molecular weight 62 to 1.15 million, NovaMatrix FMC BI0P0LYMER, USA) 1 g was dissolved in 200 ml of distilled water to obtain a clear transparent solution.
- 2.64 g of DGDTPDH prepared in Example 1 was added to the above solution, and dissolved by stirring. Then, the pH of the solution was adjusted to 0.75 by using 0.1 mol/L hydrochloric acid, and 0.9 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Aldrich, United States), electricity Magnetic stirring. ⁇ The pH of the solution was maintained at 4.75.
- the viscosity of the solution increased and a gel formed in about 10 minutes. After the gel was formed, the reaction was allowed to stand at room temperature for 2 hours. Then, 20 g of dithiothreitol (Diagnostic Chemical Limited, USA) and a small amount of 0.1 mol/L sodium hydroxide solution were added and stirred. 5 ⁇ The pH of the solution was maintained at 8.5. After the gel was completely dissolved, the reaction was stirred at room temperature for 24 hours. Thereafter, 6 mol/liter of hydrochloric acid was added to the above solution until about pH 3. 0.
- dithiothreitol Diagnostic Chemical Limited, USA
- the solution was loaded into a dialysis tube (molecular weight cutoff 3500, Sigma, USA), dialyzed against 10 liters of 0.001 mol/L hydrochloric acid and 0.3 mol/L sodium chloride solution for 5 days, and dialyzed every 8 hours. The solution was then dialyzed against 10 liters of a 0.001 molar/liter hydrochloric acid solution for 3 days, and the dialysate was changed every 8 hours. 5 ⁇ The solution was collected in the form of a white flocculent solid.
- the gel liquid chromatography (GPC) detection (pure water as mobile phase, UV 210 nm absorption detection) showed no small molecular impurity elution peaks, indicating low substitution and high substitution HA-prepared in Example 2 and Example 3. DGDTPDH is highly purified with impurities below the instrumental level.
- the side substitution degree of the low-substituted HA-DGDTPDH prepared in Example 2 was calculated to be 27% according to the area of the absorption peak, and the high substitution prepared in Example 3 was used.
- the side chain substitution degree of HA-DGDTPDH was 59%.
- the active thiol content of HA-DGDTPDH prepared in Example 2 and Example 3 was tested using the modified Ellman method reported by Shu et al., Biomacromolecules, 3, 1304, 2002.
- the side chain active thiol content of the low-substituted HA-DGDTPDH prepared in Example 2 was 25. 4 thiol/100 hyaluronic acid disaccharide repeating units, and the side chain active thiol content of the highly substituted HA-DGDTPDH prepared in Example 3 was 55. . 1 thiol/100 hyaluronic acid disaccharide repeating unit. Basically consistent with the results of hydrogen spectroscopy.
- Example 5 Synthesis of dithiodipropionate bisamidopropionic acid dihydrazide (DADTPDH) 10 g of dithiodipropionic acid (Aldrich, USA), 50 ml of anhydrous dimethyl group in a 1000 ml beaker. Formamide. After stirring at room temperature, 17.0 g of carbonyldiimidazole (Aldrich, USA) was added. At this point the solution produced a large amount of carbon dioxide bubbles and a white precipitate. The reaction was reduced under reduced pressure at room temperature for 3 hours. Then, 14.7 g of ethyl aminopropionate hydrochloride (Aldrich, USA) was added, and the reaction was stirred for 1 hour.
- DADTPDH dithiodipropionate bisamidopropionic acid dihydrazide
- Sodium hyaluronate (molecular weight 62.15 million, Nova atrix FC BI0P0LYMER, USA) 1 gram was dissolved in 200 ml of distilled water to obtain a clear transparent solution. 1.43 g of DADTPDH prepared in Example 5 was added to the above solution, and dissolved by stirring. Then, the pH of the solution was adjusted to 4.75 with 0.1 mol/L hydrochloric acid, and added to 0. 48 g of 1-ethyl. -3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Aldrich) , United States), electromagnetic stirring. ⁇ The pH of the solution was maintained at 4.75.
- the viscosity of the solution increased and a gel formed in about 10 minutes. After the gel is formed, it is allowed to stand at room temperature. Reaction for 2 hours. Then, 12 g of dithiothreitol (Diagnostic Chemical Limited, USA) and a small amount of 0.1 mol/L sodium hydroxide solution were added and stirred. 5 ⁇ The pH of the solution was maintained at 8.5. After the gel was completely dissolved, the reaction was stirred at room temperature for 24 hours. Thereafter, 6 mol/liter of hydrochloric acid was added to the above solution until about pH 3. 0.
- the solution was loaded into a dialysis tube (molecular weight cutoff 3500, Sigma, USA), dialyzed against 10 liters of 0.001 mol/L hydrochloric acid and 0.3 mol/L sodium chloride solution for 5 days, and dialyzed every 8 hours. The solution was then dialyzed against 10 liters of a 0.001 molar/liter hydrochloric acid solution for 3 days, and the dialysate was changed every 8 hours. 5 ⁇ The solution was collected in the form of a white flocculent solid.
- GPC detection (pure water for mobile phase, UV 210 nm absorption detection) showed no peaks of small molecular impurities, indicating that the synthesized HA-DADTPDH was highly purified, and the impurities were lower than the instrument detection level.
- HA-DADTPDH Hydrogen nuclear magnetic resonance spectroscopy detection (- NMR) (D 2 0 as solvent).
- HA-DADTPDH has two new absorption peaks at ⁇ 3. 4, 2. 66 ppm corresponding to CH 2 G3 ⁇ 4NHC (0) CH 2 CH 2 SH and CH 2 CH 2 NHC (0) CH 2 ⁇ 3 ⁇ 4SH Hydrogen atom absorption of chain methylene; G3 ⁇ 43 ⁇ 4NHC (0) CH 2 CH 2 SH and CH 2 CH 2 NHC (0) ⁇ 3 ⁇ 4CH 2 SH
- the hydrogen absorption peaks of the two side chain methylene groups are around ⁇ 2. 5 ppm Overlapping each other.
- a small absorption peak with a chemical shift of about ⁇ 2. 8 ppm is an absorption peak of a small amount of side reaction product.
- the characteristic methyl absorption peak of the hyaluronic acid acetyl group was used as an internal standard, and the side chain substitution degree of the synthesized HA-DGDTPDH was calculated to be 61% based on the area of the absorption peak.
- the active thiol content of HA-DADTPDH was determined by the modified Ellman method reported by Shu et al. in Biomacromolecules, 3, 1304, 2002: 53. 6 thiol/100 hyaluronan disaccharide repeat units, slightly lower than hydrogen spectroscopy Test results.
- Cysteine dihydrochloride (Aldrich, USA) 100 grams was dissolved in 1500 ml of distilled water to give a clear, clear solution. To the above solution was added 4 mol/liter of sodium hydroxide until the pH of the solution was 10. Then, 133 g of succinic anhydride (Aldrich, USA) was added under electromagnetic stirring while continuously adding 4 mol/l of sodium hydroxide to maintain the pH of the solution at 7-10. After reacting for 2 hours at room temperature, 6 mol/liter of hydrochloric acid was added to the solution. . The white precipitated product was collected by filtration and washed twice with 2000 ml of distilled water. Then vacuum drying under reduced pressure to obtain a white product solid product to synthesize disuccinic bis-succinate (abbreviated as DSC) about 150 Gram, the yield is greater than 90%.
- DSC disuccinic bis-succinate
- Example 8 Synthesis and characterization of DSCDH modified hyaluronic acid thiolated derivative (HA-DSCDH) Sodium hyaluronate (molecular weight 62-1.1 million, NovaMatrix FMC BI0P0LYMER, USA) 1 g dissolved in 200 ml of distilled water, Clarify the clear solution. To the above solution, 0.99 g of DSCDH prepared in Example 7 was added and dissolved by stirring. 288 ⁇ 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (Aldrich, then added 0.
- the gel gradually dissolved while continuously adding 0.1 mol/L sodium hydroxide solution to maintain the pH of the solution at 8.5. After the gel was completely dissolved, the reaction was electromagnetically stirred at room temperature for 24 hours. Thereafter, 6 mol/liter of hydrochloric acid was added to the above solution until about pH 3. 0.
- the solution was loaded into a dialysis tube (molecular weight cutoff 3500, Sigma, USA), dialyzed against 10 liters of 0.001 mol/L hydrochloric acid and 0.3 mol/L sodium chloride solution for 5 days, and dialyzed every 8 hours. The solution was then dialyzed against 10 liters of a 0.001 molar/liter hydrochloric acid solution for 3 days, and the dialysate was changed every 8 hours. 5 ⁇ The solution was finally collected in a lysate.
- GPC detection (pure water was mobile phase, UV 210 nm absorption detection) showed no peaks of small molecular impurities, indicating that the synthesized HA-DSCDH was highly purified, and the impurities were lower than the instrument detection level.
- the characteristic methyl absorption peak of the hyaluronic acid acetyl group was used as an internal standard, and the side chain substitution degree of the synthesized HA-DGDTPDH was 38% based on the area of the absorption peak.
- the active thiol content of HA-DSCDH was determined by the modified Ellman method reported by Shu et al. in Biomacromolecules, 3, 1304, 2002: 39. One thiol/100 hyaluronan disaccharide repeat unit, basic and hydrogen spectroscopy The results are consistent.
- Example 9 Synthesis and characterization of DSCDH modified chondroitin sulfate thiolated derivative (CS-DSCDH) Chondroitin sulfate (type c, from shark cartilage, Sigma, USA) 1 gram dissolved in 100 ml of distilled water for clear and transparent Solution. To the above solution, 0. 704 g of DSCDH prepared in Example 7 was added and dissolved by stirring. 192 ⁇ 1 - Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride ⁇ 1 (The pH of the solution was adjusted to 1.75 with 0.1 mol / L hydrochloric acid, added. 11" 11, US), electromagnetic stirring.
- CS-DSCDH DSCDH modified chondroitin sulfate thiolated derivative
- Chondroitin sulfate type c, from shark cartilage, Sigma, USA
- the above solution is charged into a dialysis tube (molecular weight cut off 3,500) , Sigma, United States), dialysis with 10 liters of 0.001 mol / liter of hydrochloric acid and 0.3 mol / liter of sodium chloride solution for 5 days, every 8 hours to change the dialysate; then 10 liters of 0. 001 moles Dialysis of hydrochloric acid solution for 3 days, changing dialysate every 8 hours. 6 ⁇ The solution of the solution was lyophilized to obtain a white flocculent solid about 0.6 g.
- GPC detection (pure water was mobile phase, UV 210 nm absorption detection) showed no peaks of small molecular impurities, indicating that the synthesized CS-DSCDH was highly purified, and the impurities were lower than the instrument detection level.
- the characteristic methyl absorption peak of the acetyl group of chondroitin sulfate was used as an internal standard, and the side chain substitution degree of the synthesized CS-DGDTPDH was calculated to be 47% based on the area of the absorption peak.
- GPC standard curve of monodisperse hyaluronic acid calibration
- the active thiol content of CS-DSCDH was determined by the modified Ellman method reported by Shu et al. in Biomacromolecules, 3, 1304, 2002: 44. 2 thiol/100 chondroitin disaccharide repeat units, slightly lower than hydrogen spectroscopy Test results.
- EXAMPLES 10 Synthesis and characterization of DSCDH modified gelatin thiolated derivatives (GEL-DSCDH) Gelatin (type B, from pigskin, Sigma, USA) 1 gram was dissolved in 100 ml of distilled water to give a clear, clear solution. To the above solution, 0.75 g of DSCDH prepared in Example 7 was added and dissolved by stirring. Then, the pH of the solution was adjusted to 4.75 with 0.1 mol/L hydrochloric acid, and 1 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Aldrich, USA) was added. , electromagnetic stirring.
- GEL-DSCDH DSCDH modified gelatin thiolated derivatives
- GPC detection (pure water for mobile phase, UV 210 nm absorption detection) showed no peaks of small molecular impurities, indicating that the synthesized GEL-DSCDH was highly purified, and the impurities were lower than the instrument detection level.
- the molecular weight and its distribution were determined by GPC (standard curve of standard molecular weight polyethylene glycol): weight average molecular weight (MJ 560,000, number average molecular weight (Mschreib) 2. 10,000, molecular weight distribution 2.67.
- the active thiol content of GEL-DSCDH was measured using the modified Ellman method reported by Shu et al., Biomacromolecules, 3, 1304, 2002: 0.55 millimoles thiol/gram GEL_DSCDH.
- Cysteine dihydrochloride (Aldrich, USA) 100 grams was dissolved in 1500 ml of distilled water to give a clear, clear solution. To the above solution, 4 mol / liter of sodium hydroxide was added until the pH of the solution was 10. Then, 152 g of glutaric anhydride (Aldrich, USA) was added under electromagnetic stirring while continuously adding 4 mol / liter of sodium hydroxide to maintain the pH of the solution at 7 to 10. After reacting at room temperature for 2 hours, 6 mol/liter of hydrochloric acid was added to the solution. The white precipitated product was collected by filtration and washed twice with 2000 ml of distilled water. Then, it was dried under vacuum to obtain about 155 g of a white product solid product, glutaric acid bis-succinate (abbreviated as DGC), and the yield was more than 90%.
- DGC glutaric acid bis-succinate
- DGCDE diethyl succinic acid diethyl succinate
- Example 12 Synthesis and characterization of DGCDH modified hyaluronic acid thiolated derivative (HA-DGCDH) Sodium hyaluronate (molecular weight 62-1.1 million, NovaMatrix FMC BI0P0LYMER, USA) 1 g dissolved in 200 ml of distilled water, Clarify the clear solution. 1.53 g of the DGCDH prepared in Example 11 was added to the above solution, and dissolved by stirring. Then, the pH of the solution was adjusted to 4.75 with 0.1 mol/L hydrochloric acid, and 0. 48 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Aldrich, United States), electromagnetic stirring.
- HA-DGCDH DGCDH modified hyaluronic acid thiolated derivative
- the above solution was loaded into a dialysis tube (cutting molecular weight 3500, Sigma, USA), dialyzed against 10 liters of 0.001 mol/L hydrochloric acid and 0.3 mol/L sodium chloride solution for 5 days, and dialysis was performed every 8 hours. The solution was then dialyzed against 10 liters of a 0.001 molar/liter hydrochloric acid solution for 3 days, and the dialysate was changed every 8 hours. 5 ⁇ The solution was collected in the form of a white flocculent solid.
- GPC detection (pure water for mobile phase, UV 210 nm absorption detection) showed no peaks of small molecular impurities, indicating that the synthesized HA-DGCDH was highly purified, and the impurities were lower than the instrument detection level.
- the characteristic methyl absorption peak of the acetyl group of hyaluronic acid was used as an internal standard, and the degree of side chain substitution of the synthesized HA-DGDTPDH was 52% based on the area of the absorption peak.
- the active thiol content of HA-DSCDH was determined by the improved Ellman method reported by Shu et al. in Biomacromolecules, 3, 1304, 2002: 49. 4 thiol/100 hyaluronan disaccharide repeat units, basic and hydrogen spectroscopy The results are consistent.
- the disulfide-crosslinked gelatin hydrogel preparation The gelatin thiolated derivative of the present invention (GEL-DSCDH) prepared in Example 10 was dissolved in 10 ml of 0.1 mol / liter of phosphate buffer ( P H 7. 0 ) A clear transparent solution was obtained, and an appropriate amount of 0.1 mol/L sodium hydroxide was added to the above solution until pH 7.4. The solution was then poured into a 25 ml glass beaker and allowed to stand at room temperature for 12 hours. The viscosity of the solution gradually increased and a gel formed.
- Example 14 Preparation of a multicomponent disulfide crosslinked hydrogel
- the preparation of the disulfide-crosslinked hyaluronic acid-gelatin two-component hydrogel The hyaluronic acid thiolated derivative of the present invention (HA-DGDTPDH) prepared in Example 3 was dissolved in 10 ml of 0. 1 mol / liter of phosphoric acid 'salt buffer (pH 7. 0) to obtain a clear and transparent solution, an appropriate amount of 0.1 mol / liter of sodium hydroxide was added to the above solution until pH 7.4.
- the gelatin thiolated derivative of the present invention (GEL-DSCDH) prepared in Example 10 was dissolved in 10 ml of 0.1 ml/L phosphate buffer (pH 7.0) to obtain a clear transparent solution.
- Disulfide-bonded cross-linked chondroitin sulfate-gelatin two-component hydrogel preparation The chondroitin sulfate thiolated derivative of the present invention prepared in Example 9 (CS-DSCDH) 0. 3 g dissolved in 10 ml 0. 1 mol / liter of phosphate buffer (pH 7.0) to obtain a clear transparent solution, the appropriate amount of 0.1 mol / liter of sodium hydroxide was added to the above solution until pH 7.4.
- the gelatin thiolated derivative of the present invention (GEL-DSCDH) prepared in Example 10 was dissolved in 10 ml of 0.1 mol/L phosphate buffer (pH 7.0) to obtain a clear transparent solution.
- Example 3 prepared hyaluronic acid thiolated derivative of the invention (HA-DGDTPDH) 0. 1g dissolved in 10 ml / liter of phosphate buffer (pH 7. 0) to obtain a clear transparent solution, the appropriate amount of 0.1 mol / liter of sodium hydroxide was added to the above solution until pH 7.4.
- HA-DGDTPDH hyaluronic acid thiolated derivative of the invention
- the chondroitin sulfate thiolated derivative of the present invention (CS-DSCDH) prepared in Example 9 was dissolved in 10 ml of 0.1 mol/L phosphate buffer (pH 7.0) to obtain a clear transparent solution.
- an appropriate amount of 0.1 mol/liter of sodium hydroxide was added until pH 7.4.
- the gelatin thiolated derivative of the present invention (GEL-DSCDH) prepared in Example 10 was dissolved in 10 ml of 0.1 mol/L phosphate buffer (pH 7.0) to obtain a clear transparent solution.
- An appropriate amount of 0.1 mol/L sodium hydroxide was added until pH 7.4.
- Example 15 Preparation of a one-component polyethylene glycol divinyl sulfone crosslinked hydrogel
- the lyophilic thiolated derivative (HA-DGDTPDH) of the present invention prepared in Example 3 was dissolved in 10 ml 0.11. Mol / liter of phosphate buffer (pH 7.0) to obtain a clear transparent solution, the appropriate amount of 0.1 mol / liter of sodium hydroxide was added to the above solution until pH 7.4.
- Polyethylene glycol divinyl sulfone molecular weight 3400, Nektar Therapeutics, USA
- the sulphate chondroitin thiolated derivative (CS-DSCDH) of the present invention prepared in Example 9 was dissolved in 10 ml 0.11. Mol / liter of phosphate buffer (pH 7.0) to obtain a clear transparent solution, the appropriate amount of 0.1 mol / liter of sodium hydroxide was added to the above solution until pH 7.4. Polyethylene glycol divinyl sulfone (molecular weight 3400, Nektar Therapeutics, USA) 0. 1 gram dissolved in 2. 5 ml of 0.1 mol / liter of p-acid buffer (pH 7. 0) to obtain a clear transparent solution.
- gelatin thiolated derivative of the present invention (GEL-DSCDH) 0. 3g dissolved in 10 ml 0.1 mol / liter Phosphate buffer
- hyaluronic acid thiolated derivative of the present invention (HA-DGDTPDH) 0. 1 g dissolved in the polyethylene glycol diacrylate crosslinked hyaluronic acid-gelatin two-component hydrogel 10 ml / liter of phosphate buffer (pH 7. 0) to obtain a clear transparent solution, the appropriate amount of 0.1 mol / liter of sodium hydroxide was added to the above solution until pH 7.4.
- chondroitin sulfate thiolated derivative of the present invention prepared in Example 9 was dissolved in 10 ml of 0.1 mol/L phosphate buffer (pH 7.0) to obtain a clear transparent solution.
- an appropriate amount of 0.1 mol/liter of sodium hydroxide was added until pH 7.4.
- Example 10 Preparation of the gelatin thiolated derivative of the present invention (GEL-DSCDH) 0.3 g dissolved in 10 ml of 0.1 mol/L phosphate buffer (pH 7.0) to obtain a clear transparent solution, dissolved in the above Add an appropriate amount of 0.1 mol / liter of sodium hydroxide until ⁇ ⁇ 7. 4.
- Polyethylene glycol diacrylate (molecular weight 3400, Nektar Therapeutics, USA) 0. 3 g dissolved in 7.5 ml of 0.1 mol/L phosphate buffer (pH 7.0) gave a clear clear solution. Then, the above 10 ml of HA-DGDTPDH solution, 10 ml of CS-DSCDH solution, 10 ml of GEL-DSCDH solution, and 7.5 ml of polyethylene glycol diacrylate solution were simultaneously poured into a 50 ml glass beaker, and electromagnetic stirring was immediately performed for 30 seconds. Allow to stand at room temperature for 30 minutes. The viscosity of the solution gradually increases and forms a gel.
- Disulfide-bonded cross-linked hyaluronic acid hydrogel for inhibiting cell adhesion A disulfide-crosslinked hyaluronic acid hydrogel was prepared in a 24-well standard cell culture plate according to Example 13, per well. 1 ml. After 12 hours, the whole cell culture plate was immersed in a 75% alcohol solution for 2 hours. Thereafter, the cell culture plate was washed three times with sterile physiological saline. 1 ml of cell culture medium (DMEM, 10% bovine serum) and 20,000 NIH 3T3 fibroblasts were added to each well. Incubate for 24 hours at 37 ° C in a CO2 cell culture incubator.
- DMEM cell culture medium
- 20,000 NIH 3T3 fibroblasts were added to each well. Incubate for 24 hours at 37 ° C in a CO2 cell culture incubator.
- Example 18 Disulfide-bonded cross-linked hyaluronic acid-gelatin two-component hydrogel as a substrate for cell adhesion growth
- a disulfide-crosslinked hyaluronic acid-gelatin two-component hydrogel was prepared in a 24-well standard cell culture plate according to Example 14 at a volume of 1 ml per well. After 12 hours, the whole cell culture plate was immersed in 75% alcohol solution for 2 hours. Thereafter, the cell culture plate was washed three times with sterile physiological saline. Add 1 ml of cell culture medium (DMEM, 10% bovine serum) and 20,000 NIH 3T3 fibroblasts to each well. Incubate at 37 ° C for 24 hours in a carbon dioxide cell culture incubator.
- DMEM cell culture medium
- 20,000 NIH 3T3 fibroblasts 20,000 NIH 3T3 fibroblasts
- Example 19 Polyethylene glycol divinyl sulfone crosslinked hyaluronic acid hydrogel for inhibiting cell adhesion
- Polyethylene glycol divinyl sulfone crosslinked hyaluronic acid was prepared according to Example 15 in a 24-well standard cell culture plate. Acid hydrogel, 1 ml per well. After 12 hours, the whole cell culture plate was immersed in 75% alcohol solution for 2 hours. Thereafter, the cell culture plate was washed three times with sterile physiological saline. Add 1 ml of cell culture medium (DMEM, 10% bovine serum) and 20,000 NIH 3T3 fibroblasts to each well. The cells were cultured in a carbon dioxide cell incubator at 37 ° C for 24 hours.
- DMEM 10% bovine serum
- Example 20 Polyethylene glycol diacrylate crosslinked hyaluronic acid-gelatin two-component hydrogel as a substrate for cell adhesion growth
- a polyethylene glycol diacrylate crosslinked hyaluronic acid-gelatin two-component hydrogel was prepared in accordance with Example 16 in a 24-well standard cell culture plate at 1 ml per well. After 12 hours, the whole cell culture plate was immersed in a 75% alcohol solution for 2 hours. Thereafter, the cell culture plate was washed three times with sterile physiological saline. 1 ml of cell culture medium (DMEM, 10% bovine serum) and 20,000 NIH 3T3 fibroblasts were added to each well. Incubate at 37 ° C for 24 hours in a carbon dioxide cell culture incubator.
- DMEM 10% bovine serum
- the polymer thiolated modified derivative of the formula (I) or (II) of the present invention has many beneficial effects.
- the invention adopts the chemical bonding mode of the hydrazide bond to carry out the thiolation modification, and has many remarkable advantages such as mild preparation conditions, high yield, high degree of modification and controllability.
- the invention can conveniently prepare various disulfide-bonded crosslinked polymer materials: a disulfide cross-linking material of a polysaccharide, a disulfide cross-linking material of a protein, or a complex disulfide cross-linking of two polysaccharides.
- Materials composite crosslinked materials of two proteins, a composite disulfide crosslinked material of a polysaccharide and a protein, and the like.
- These disulfide-bonded polymer materials can be formed into various forms such as a film, a sponge, and a gel, and can be used for inhibiting cell adhesion, using as a cell growth substrate, and the like.
- the cross-linking action of the thiol-reactive cross-linking agent and the polymer thiolated modified derivative of the formula (I) or (II) of the present invention is very fast, and the cross-linking gelation rate is higher than that of the disulfide bond.
- the speed of the joint is increased by more than 5 times and has important biomedical uses, such as in-situ embedding of cells.
- the invention can conveniently prepare various sulfhydryl reactive cross-linking cross-linking polymer materials: for example, a cross-linking material of a polysaccharide, a cross-linking material of a protein, or a composite cross-linking material of two polysaccharides, two proteins Composite cross-linking materials, a composite cross-linking material of a polysaccharide and a protein, and the like.
- thiol-reactive cross-linked polymeric materials can be used in various forms such as films, sponges, and gels, and can be used for inhibiting cell adhesion, using as a cell growth substrate, and the like.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Peptides Or Proteins (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07816478.7A EP2103631B1 (en) | 2006-12-11 | 2007-09-29 | Mercapto-group modified macromolecule derivative and cross-linked material |
JP2009540576A JP5211064B2 (ja) | 2006-12-11 | 2007-09-29 | チオール修飾高分子誘導体およびその架橋材料 |
AU2007332031A AU2007332031A1 (en) | 2006-12-11 | 2007-09-29 | Thiol-Modified Macromolecule Derivatives and Cross-Linked Materials Thereof |
CA2672019A CA2672019C (en) | 2006-12-11 | 2007-09-29 | Thiol-modified macromolecule derivatives and cross-linked materials thereof |
US12/518,473 US8124757B2 (en) | 2006-12-11 | 2007-09-29 | Thiol-modified macromolecule derivatives and cross-linked materials thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610119414A CN101200504B (zh) | 2006-12-11 | 2006-12-11 | 高分子巯基化改性衍生物及其交联材料 |
CN200610119414.1 | 2006-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008071058A1 true WO2008071058A1 (fr) | 2008-06-19 |
Family
ID=39511244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2007/002864 WO2008071058A1 (fr) | 2006-12-11 | 2007-09-29 | Dérivé macromoléculaire modifié par un groupe mercapto et matériau réticulé |
Country Status (7)
Country | Link |
---|---|
US (1) | US8124757B2 (zh) |
EP (1) | EP2103631B1 (zh) |
JP (1) | JP5211064B2 (zh) |
CN (1) | CN101200504B (zh) |
AU (1) | AU2007332031A1 (zh) |
CA (1) | CA2672019C (zh) |
WO (1) | WO2008071058A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9446067B2 (en) | 2010-09-09 | 2016-09-20 | Bioregen Biomedical (Changzhou) Co. Ltd. | Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof |
CN109459503A (zh) * | 2017-09-06 | 2019-03-12 | 上海绿谷制药有限公司 | 一种测定肝素类药物重均分子量和含量的方法 |
WO2019240219A1 (ja) | 2018-06-14 | 2019-12-19 | 持田製薬株式会社 | 新規な架橋アルギン酸 |
WO2021125255A1 (ja) | 2019-12-18 | 2021-06-24 | 持田製薬株式会社 | 新規な架橋アルギン酸 |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101220090B (zh) * | 2007-01-09 | 2010-10-13 | 上海百瑞吉生物医药有限公司 | 明胶多重改性衍生物及其交联材料 |
CN101338036B (zh) * | 2007-07-06 | 2010-11-03 | 常州百瑞吉生物医药有限公司 | 生物相容快速凝胶化水凝胶及其喷雾剂的制备方法 |
CN101721349B (zh) | 2008-10-16 | 2011-07-20 | 常州百瑞吉生物医药有限公司 | 可注射原位交联水凝胶及其制备方法和用途 |
EP2459239A1 (en) | 2009-07-30 | 2012-06-06 | Carbylan Biosurgery, Inc. | Modified hyaluronic acid polymer compositions and related methods |
WO2011090428A1 (en) * | 2010-01-19 | 2011-07-28 | Organoclick Ab | Heterogeneous thiol-ene click modifications of solid polysaccharide-based materials |
HUE043040T2 (hu) | 2010-11-23 | 2019-07-29 | Allergan Pharmaceuticals Int Ltd | Poliszacharid keresztkötéseket tartalmazó fehérje készítmény és/vagy formula |
CN102408496B (zh) * | 2011-09-13 | 2013-02-06 | 武汉理工大学 | 一种原位交联海藻酸钠水凝胶及其制备方法 |
CN102617852B (zh) * | 2012-04-24 | 2013-07-17 | 华东师范大学 | 马来酰亚胺-聚谷氨酸-天冬氨酸聚合物和其复合物、及其制备方法和用途 |
CN102690516B (zh) * | 2012-06-11 | 2013-12-18 | 哈尔滨工程大学 | 一种可生物降解交联壳聚糖螯合树脂及其制备方法 |
CN103613686B (zh) * | 2013-11-12 | 2015-08-19 | 广州恩轲肽医药科技有限公司 | 巯基化透明质酸的制备方法及其应用 |
CN103936883B (zh) * | 2014-03-25 | 2015-12-30 | 中国医学科学院生物医学工程研究所 | 含巯基壳聚糖衍生物及复合物纳米粒子及制备方法 |
ITRM20150204A1 (it) * | 2015-05-13 | 2016-11-13 | Nanofaber S R L | Microspugne di acido ialuronico e metodo per la preparazione delle stesse |
CN104958783B (zh) * | 2015-06-19 | 2017-08-08 | 暨南大学 | 一种天然多糖基水凝胶及制备和在眼结膜修复中的应用 |
CN105273105B (zh) * | 2015-11-13 | 2018-02-16 | 华东理工大学 | 改性海藻酸钠及其用途 |
TWI660740B (zh) | 2016-10-21 | 2019-06-01 | 財團法人工業技術研究院 | 水膠組合物及包含其之藥物傳輸系統 |
CN109096483B (zh) * | 2017-06-28 | 2020-09-04 | 北京键凯科技股份有限公司 | 分枝型多元甘醇环氧衍生物交联透明质酸钠凝胶及其制备和应用 |
CN109265705A (zh) * | 2017-07-18 | 2019-01-25 | 中国科学院苏州纳米技术与纳米仿生研究所 | 胶原巯基化衍生物及其制备方法和应用 |
CN107929804A (zh) * | 2017-12-26 | 2018-04-20 | 常州百瑞吉生物医药有限公司 | 改性明胶基复合海绵及其制备方法和用途 |
CN108096637B (zh) * | 2017-12-27 | 2020-09-18 | 上海其胜生物制剂有限公司 | 一种梯度仿生人工玻璃体的制备方法 |
CN111868096B (zh) * | 2018-03-28 | 2022-06-17 | 持田制药株式会社 | 反应性海藻酸衍生物 |
CN110343264B (zh) * | 2018-04-03 | 2021-11-26 | 中国科学院苏州纳米技术与纳米仿生研究所 | 壳聚糖水凝胶及其制备方法与应用 |
CN110408050B (zh) * | 2018-04-28 | 2021-11-23 | 南京理工大学 | 纤维素基接枝改性可逆凝胶及其制备方法 |
CA3101410A1 (en) | 2018-06-15 | 2019-12-19 | Croma-Pharma Gmbh | Stabilized hyaluronic acid |
MX2020013006A (es) | 2018-06-15 | 2021-03-25 | Croma Pharma Gmbh | Composicion de hidrogel que comprende polimero reticulado. |
US11795320B2 (en) * | 2019-09-20 | 2023-10-24 | Bausch + Lomb Ireland Limited | Grafted polymer and use thereof |
EP4035735A4 (en) * | 2019-09-25 | 2023-10-18 | Mochida Pharmaceutical Co., Ltd. | NOVEL STRUCTURE OF CROSS-LINKED ALGINIC ACID |
CN112812329B (zh) * | 2019-11-18 | 2023-06-16 | 孛朗孚(杭州)生物科技有限公司 | 巯基改性高分子化合物的水凝胶及其制备方法和用途 |
CN112812201B (zh) | 2019-11-18 | 2023-06-16 | 孛朗孚(杭州)生物科技有限公司 | 巯基改性透明质酸及其制备方法和用途 |
CN112812200B (zh) | 2019-11-18 | 2023-06-16 | 孛朗孚(杭州)生物科技有限公司 | 巯基改性高分子化合物及其制备方法和用途 |
CN112842929A (zh) * | 2019-11-27 | 2021-05-28 | 华熙生物科技股份有限公司 | 一种巯基化透明质酸及其制备方法和应用 |
CN111068099B (zh) * | 2019-12-11 | 2021-04-06 | 杭州千芝雅卫生用品有限公司 | 高分子吸收聚合体、制备方法及其用途 |
CA3157952A1 (en) | 2019-12-19 | 2021-06-24 | Ralph Hollaus | Thiol-modified hyaluronan and hydrogel comprising the crosslinked hyaluronan |
CN112358628B (zh) * | 2020-11-09 | 2022-06-21 | 华中科技大学同济医学院附属协和医院 | 一种使用牺牲材料为水凝胶及生物材料进行脱模的方法 |
CN113185716B (zh) * | 2021-04-20 | 2022-04-22 | 中国海洋大学 | 一种巯基化透明质酸多糖水凝胶及其制备方法和应用 |
CN114409911B (zh) * | 2021-12-15 | 2023-06-27 | 广州宝会树脂有限公司 | 一种高保水的SiO2改性丙烯酸吸水树脂的制备方法 |
CN114478829B (zh) * | 2021-12-31 | 2023-07-28 | 常州百瑞吉生物医药有限公司 | 一种透明质酸交联活性材料组合物、制备方法及应用 |
CN114316087B (zh) * | 2021-12-31 | 2022-10-28 | 常州百瑞吉生物医药有限公司 | 一种透明质酸交联活性材料、制备方法及其应用 |
CN114716581A (zh) * | 2022-03-25 | 2022-07-08 | 常州百瑞吉生物医药有限公司 | 一种多重改性透明质酸衍生物及其应用 |
CN115785490A (zh) * | 2022-11-29 | 2023-03-14 | 广西医科大学 | 一种交联改性的明胶材料及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6357569A (ja) * | 1986-08-28 | 1988-03-12 | Teijin Ltd | ヒドラジド化合物及びその製造方法 |
WO2004003716A1 (fr) | 2002-06-27 | 2004-01-08 | Tai Guen Enterprise Co.,Ltd | Dispositif de traitement de donnee integre portable a interface de donnees standard |
US20040038934A1 (en) * | 2001-02-22 | 2004-02-26 | Anika Therapeutics, Inc. | Thiol-modified hyaluronan |
WO2004037164A2 (en) * | 2002-06-21 | 2004-05-06 | University Of Utah Research Foundation | Crosslinked compounds and methods of making and using thereof |
WO2005056608A1 (en) * | 2003-12-04 | 2005-06-23 | University Of Utah Research Foundation | Modified macromolecules and methods of making and using thereof |
US20060110458A1 (en) * | 2002-11-21 | 2006-05-25 | Chugai Seiyaku Kabushiki Kaisha | Sustained release drug carrier |
EP1683812A1 (en) * | 2003-11-14 | 2006-07-26 | Chugai Seiyaku Kabushiki Kaisha | Crosslinked polysaccharide microparticles and method for their preparation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5157123A (en) * | 1989-03-13 | 1992-10-20 | Georgetown University | S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent |
WO2000053577A1 (en) * | 1999-03-12 | 2000-09-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Hydrazide inhibitors of hiv-1 integrase |
JP2003019869A (ja) * | 2001-07-09 | 2003-01-21 | Oji Paper Co Ltd | 感熱記録体 |
ATA13842001A (de) * | 2001-08-31 | 2002-10-15 | Mucobiomer Biotechnologische F | Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung |
CN1186357C (zh) * | 2003-03-14 | 2005-01-26 | 王立强 | 壳聚糖巯基醋酸偶合物的新合成工艺 |
EP1624935B1 (en) * | 2003-05-15 | 2016-09-28 | The University of Utah Research Foundation | Anti-adhesion composites and methods os use thereof |
EP1741723A1 (en) * | 2004-04-28 | 2007-01-10 | Yamaha Hatsudoki Kabushiki Kaisha | ß-CHITIN COMPLEX AND METHOD FOR PRODUCING THE SAME |
CN100497443C (zh) * | 2006-02-10 | 2009-06-10 | 天津理工大学 | 制备巯基聚天冬氨酸与壳聚糖共聚物的方法与用途 |
-
2006
- 2006-12-11 CN CN200610119414A patent/CN101200504B/zh active Active
-
2007
- 2007-09-29 JP JP2009540576A patent/JP5211064B2/ja active Active
- 2007-09-29 CA CA2672019A patent/CA2672019C/en active Active
- 2007-09-29 EP EP07816478.7A patent/EP2103631B1/en active Active
- 2007-09-29 WO PCT/CN2007/002864 patent/WO2008071058A1/zh active Application Filing
- 2007-09-29 AU AU2007332031A patent/AU2007332031A1/en not_active Abandoned
- 2007-09-29 US US12/518,473 patent/US8124757B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6357569A (ja) * | 1986-08-28 | 1988-03-12 | Teijin Ltd | ヒドラジド化合物及びその製造方法 |
US20040038934A1 (en) * | 2001-02-22 | 2004-02-26 | Anika Therapeutics, Inc. | Thiol-modified hyaluronan |
WO2004037164A2 (en) * | 2002-06-21 | 2004-05-06 | University Of Utah Research Foundation | Crosslinked compounds and methods of making and using thereof |
WO2004003716A1 (fr) | 2002-06-27 | 2004-01-08 | Tai Guen Enterprise Co.,Ltd | Dispositif de traitement de donnee integre portable a interface de donnees standard |
US20060110458A1 (en) * | 2002-11-21 | 2006-05-25 | Chugai Seiyaku Kabushiki Kaisha | Sustained release drug carrier |
EP1683812A1 (en) * | 2003-11-14 | 2006-07-26 | Chugai Seiyaku Kabushiki Kaisha | Crosslinked polysaccharide microparticles and method for their preparation |
WO2005056608A1 (en) * | 2003-12-04 | 2005-06-23 | University Of Utah Research Foundation | Modified macromolecules and methods of making and using thereof |
Non-Patent Citations (5)
Title |
---|
BIOMACROMOLECULES, vol. 3, 2002, pages 1304 |
SHU ET AL., BIOMACROMOLECULES, vol. 3, 2002, pages 1304 |
SHU ET AL., BIOMATERIALS, vol. 24, 2003, pages 3825 |
SHU, BIOMACROMOLECULES, vol. 3, 2002, pages 1304 |
XIAO Z. ET AL.: "Disulfide Cross-Linked Hyaluronan Hydrogels", BIOMACROMOLECULES, vol. 3, no. 6, 2002, pages 1304 - 1311, XP002975311 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9446067B2 (en) | 2010-09-09 | 2016-09-20 | Bioregen Biomedical (Changzhou) Co. Ltd. | Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof |
US10064889B2 (en) | 2010-09-09 | 2018-09-04 | Bioregen Biomedical (Changzhou) Co., Ltd. | Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof |
CN109459503A (zh) * | 2017-09-06 | 2019-03-12 | 上海绿谷制药有限公司 | 一种测定肝素类药物重均分子量和含量的方法 |
WO2019240219A1 (ja) | 2018-06-14 | 2019-12-19 | 持田製薬株式会社 | 新規な架橋アルギン酸 |
KR20210019441A (ko) | 2018-06-14 | 2021-02-22 | 모찌다 세이야쿠 가부시끼가이샤 | 신규 가교 알긴산 |
US11932708B2 (en) | 2018-06-14 | 2024-03-19 | Mochida Pharmaceutical Co., Ltd. | Crosslinked alginic acid |
WO2021125255A1 (ja) | 2019-12-18 | 2021-06-24 | 持田製薬株式会社 | 新規な架橋アルギン酸 |
Also Published As
Publication number | Publication date |
---|---|
CA2672019A1 (en) | 2008-06-19 |
CN101200504B (zh) | 2010-05-12 |
EP2103631A4 (en) | 2011-08-24 |
CN101200504A (zh) | 2008-06-18 |
JP5211064B2 (ja) | 2013-06-12 |
EP2103631A1 (en) | 2009-09-23 |
CA2672019C (en) | 2012-12-04 |
US8124757B2 (en) | 2012-02-28 |
JP2010512433A (ja) | 2010-04-22 |
EP2103631B1 (en) | 2017-06-28 |
US20100152423A1 (en) | 2010-06-17 |
AU2007332031A1 (en) | 2008-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008071058A1 (fr) | Dérivé macromoléculaire modifié par un groupe mercapto et matériau réticulé | |
CN108310460B (zh) | 可注射高强度温敏性改性甲壳素基水凝胶及其制备方法和应用 | |
Guaresti et al. | In situ cross–linked chitosan hydrogels via Michael addition reaction based on water–soluble thiol–maleimide precursors | |
WO2009006780A1 (fr) | Procédé pour la formation d'un hydrogel biocompatible à gélification rapide et préparation d'un agent de pulvérisation | |
WO2021237864A1 (zh) | 聚乙二醇衍生物、其制备方法及可快速发生交联反应的聚乙二醇水凝胶 | |
CN110522948B (zh) | 可注射水凝胶及其制备方法和应用 | |
WO2004022603A1 (en) | Hyaluronic acid derivatives and processes for preparing the same | |
Le Thi et al. | Enzymatically crosslinkable hyaluronic acid-gelatin hybrid hydrogels as potential bioinks for tissue regeneration | |
JP5357779B2 (ja) | 多重修飾されたゼラチン誘導体およびその架橋材料 | |
JPH09508926A (ja) | 表面及び分子の変性に用いる単離可能で水溶性で加水分解に対して安定なポリ(エチレングリコール)と関連ポリマーの活性スルホン類 | |
US20120094955A1 (en) | Method of dissolving an oxidized polysaccharide in an aqueous solution | |
WO2010118285A1 (en) | Method of dissolving an oxidized polysaccharide in an aqueous solution | |
WO2022170681A1 (zh) | 一种可降解的双组份水凝胶及其制备方法与应用 | |
CN114478831B (zh) | 一种高分子材料及其制备方法与应用 | |
CN111484611B (zh) | 含有硫酯与醛基的聚乙二醇聚合物及其制备方法、包含其的化学交联水凝胶与应用 | |
CN112812201B (zh) | 巯基改性透明质酸及其制备方法和用途 | |
CN110128662B (zh) | 一种水溶性硫醇封端的peg官能化poss交联剂及其制备方法和应用 | |
CN112842929A (zh) | 一种巯基化透明质酸及其制备方法和应用 | |
EP1659143A1 (en) | Temperature-responsive hydrogel | |
CN115466411B (zh) | 一种双硫键交联透明质酸水凝胶的制备方法 | |
WO2019192628A2 (zh) | 壳聚糖巯基化衍生物、壳聚糖水凝胶及其制备方法与应用 | |
CN116328022A (zh) | 可注射型仿贻贝壳聚糖水凝胶粘合剂的制备方法及应用 | |
CN116139334A (zh) | 强粘附可注射型透明质酸双网络水凝胶及其制备方法 | |
JP2005075815A (ja) | 止血性組織修復材 | |
CN117503986B (zh) | 具有双层网络结构的可注射湿黏附水凝胶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07816478 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2672019 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009540576 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12518473 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2007816478 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007332031 Country of ref document: AU Ref document number: 2007816478 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4027/CHENP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2007332031 Country of ref document: AU Date of ref document: 20070929 Kind code of ref document: A |